Group 1 - The company has completed all professional review work for its innovative Class 1 drug and has entered the comprehensive review stage, indicating it is nearing approval [2] - The specific drug in question is the chemical Class 1 new drug, Amber Dihydroaminoacridine Tablets, which is currently undergoing normal review processes [2] - The company will disclose relevant information about the new drug according to regulations and requirements, urging investors to pay attention to company announcements [2]

Core Viewpoint - The company is advancing its innovative drug, Succinyl-8-hydroxyl-aminocarbazole tablets, aimed at treating Alzheimer's disease, which is expected to support its strategic goals of Asianization of traditional Chinese medicine and internationalization of chemical drugs [1]. Group 1 - The company has completed all professional review work for the new chemical drug and is currently in the comprehensive review phase, with all evaluations proceeding normally [1]. - The company plans to continue its deep layout in the neurological product pipeline and platform construction [1]. - Relevant information regarding the new drug will be disclosed according to regulations and requirements, and investors are encouraged to pay attention to company announcements [1].

11月17日，通化金马盘中上涨2.23%，截至11:05，报29.39元/股，成交3.93亿元，换手率1.41%，总市值 284.05亿元。 资金流向方面，主力资金净流出1759.63万元，特大单买入2862.41万元，占比7.28%，卖出4253.98万 元，占比10.82%；大单买入1.15亿元，占比29.36%，卖出1.19亿元，占比30.29%。 通化金马所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：民营医院、工业大麻、 东北振兴、肝炎治疗、中药等。 截至9月30日，通化金马股东户数3.82万，较上期减少3.20%；人均流通股25266股，较上期增加3.31%。 2025年1月-9月，通化金马实现营业收入8.92亿元，同比减少7.88%；归母净利润2496.35万元，同比增长 4.35%。 分红方面，通化金马A股上市后累计派现2.10亿元。近三年，累计派现0.00元。 机构持仓方面，截止2025年9月30日，通化金马十大流通股东中，创新药（159992）位居第七大流通股 东，持股919.30万股，相比上期增加8.78万股。南方中证1000ETF（512100）位居第八大流通股东，持 ...

Core Viewpoint - Tonghua Jinma (000766) is advancing its research on a new chemical drug, Amber Dihydroaminoacridine Tablets, aimed at treating mild to moderate Alzheimer's disease, with the review process currently in the comprehensive evaluation stage [1] Group 1 - The new drug has completed all professional review work and is now in the comprehensive evaluation phase [1] - The company will disclose any information that meets the disclosure standards as per relevant regulations [1]

Core Viewpoint - The company has developed a new chemical drug, Amber Tetrahydroaminoacridine Tablets, aimed at treating mild to moderate Alzheimer's disease, and it is currently in the comprehensive review stage after completing all professional evaluation work [1]. Group 1 - The new drug is classified as a Class 1 chemical new drug [1]. - The company assures that it will disclose any information that meets the disclosure standards as per relevant regulations [1]. - The review process for the new drug is progressing normally [1].

Group 1 - The company held its 9th temporary board meeting of the 11th session on November 12, 2025, with all 9 directors present [1][2][3] - The board approved the reappointment of Beijing Dehao International Accounting Firm as the auditor for the fiscal year 2025, which requires shareholder approval [5][6][8] - The board also approved a guarantee limit of RMB 160 million for its wholly-owned subsidiaries, with specific allocations for Harbin Shengtai Biological Pharmaceutical Co., Ltd. and Chengdu Yongkang Pharmaceutical Co., Ltd. [9][10][17] Group 2 - The company plans to hold its 4th temporary shareholders' meeting on November 28, 2025, to discuss the approved proposals from the board meeting [14][55] - The meeting will allow for both on-site and online voting, with specific timeframes for participation [56][70] - The company has ensured compliance with relevant laws and regulations for the meeting's organization [54][61] Group 3 - The total external guarantee balance after the new guarantees will be RMB 203.305 million, which represents 90.14% of the company's audited net assets for 2024 [26][36] - The guarantees are exclusively for wholly-owned subsidiaries, with no overdue guarantees or litigation related to the guarantees reported [26][36] - The board believes that the guarantees will enhance decision-making efficiency and support the subsidiaries' operational needs [24][34] Group 4 - The company has a strong credit rating and has not been subject to any significant legal or financial penalties [20][21][31] - The financial health of the subsidiaries, including their debt ratios, has been considered in the guarantee approvals [17][19] - The company aims to utilize its resources effectively to support its subsidiaries while managing associated risks [24][34]

（编辑 任世碧） 证券日报网讯 11月12日晚间，通化金马发布公告称，公司第十一届董事会2025年第九次临时会议于 2025年11月12日召开，会议审议通过了《关于全资子公司为母公司提供担保额度预计的议案》。公司全 资子公司成都永康制药有限公司及哈尔滨圣泰生物制药有限公司拟根据实际情况共同为母公司融资贷款 提供担保额度不超过35，000万元。其中：共同为母公司在中国建设银行股份有限公司通化分行融资贷 款提供担保额度不超过15，000万元，共同为母公司在吉林银行股份有限公司通化新华支行融资贷款提 供担保额度不超过20，000万元。 ...

证券日报网讯 11月12日晚间，通化金马发布公告称，公司第十一届董事会2025年第九次临时会议于 2025年11月12日召开，会议审议通过了《关于公司对下属子公司担保额度预计的议案》。公司对全资子 公司提供担保额度为人民币16，000万元。其中：为哈尔滨圣泰生物制药有限公司提供担保的额度不超 过8，000万元，该公司最近一期资产负债率超过70%；为成都永康制药有限公司提供担保的额度不超过 8，000万元，该公司最近一期资产负债率低于70%。 （文章来源：证券日报） ...

每经AI快讯，通化金马（SZ 000766，收盘价：28.44元）11月12日晚间发布公告称，本次担保提供后， 公司及控股子公司实际对外担保余额约为20.33亿元，占公司2024年度经审计净资产的90.14%，全部为 公司对合并报表范围内全资子公司的担保和合并报表范围内子公司对母公司的担保。 2025年1至6月份，通化金马的营业收入构成为：制药占比100.0%。 截至发稿，通化金马市值为275亿元。 每经头条（nbdtoutiao）——谁在替王家卫写《繁花》？揭秘影视剧本层层转包"枪手链" （记者 王瀚黎） ...

证券代码：000766 证券简称：通化金马 公告编号：2025-42 通化金马药业集团股份有限公司 关于公司对下属子公司担保额度预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 本次担保全部为上市公司对下属全资子公司的担保。其中被担保人子公司哈尔 滨圣泰生物制药有限公司最近一期（2024 年 12 月 31 日）资产负债率超过 70%。本 次担保提供后公司及控股子公司实际对外担保余额为 184,305 万元，占公司最近一 期经审计净资产的 81.72%。 通化金马药业集团股份有限公司（以下简称"公司"）第十一届董事会 2025 年 第九次临时会议于 2025 年 11 月 12 日召开，会议审议通过了《关于公司对下属子公 司担保额度预计的议案》。具体情况公告如下： 一、担保情况概述 （一）担保事项的基本情况 注：1、表内"最近一期"数据取自 2024 年 12 月 31 日经审计数据； 2、表内担保方持股比例均为穿透后的持股比例，被担保方均为担保方全资子公 司或孙公司。 （二）担保事项的审批情况 公司第十一届董事会 2025 年第九次临时 ...